BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BVXV

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/01	05 : 06	Edgar (US Regulatory)	Form NT 20-F - Notification of inability to timely file Form 20-F	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/04/17	06 : 27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/04/10	20 : 00	PR Newswire (US)	Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/03/13	05 : 17	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/03/12	21 : 00	PR Newswire (US)	Scinai leadership to attend BIO-Europe Spring 2024	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/02/13	21 : 00	PR Newswire (US)	Scinai Welcomes Liat Halpert as Head of Business Development and Sales	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2024/01/05	06 : 01	PR Newswire (US)	Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/11/20	21 : 30	PR Newswire (US)	Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/09/08	06 : 27	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/09/07	01 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/09/07	00 : 44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/09/06	19 : 00	GlobeNewswire Inc.	BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/29	05 : 01	Edgar (US Regulatory)	Form 424B2 - Prospectus [Rule 424(b)(2)]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/28	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/25	05 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/23	19 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/19	05 : 16	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/18	23 : 07	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/14	19 : 08	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/11	22 : 44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/11	22 : 00	GlobeNewswire Inc.	BiondVax Reports Second Quarter Financial Results and Provides Business Update	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/02	05 : 01	GlobeNewswire Inc.	Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/08/02	05 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/07/13	04 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/07/11	21 : 17	GlobeNewswire Inc.	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/07/05	22 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/07/04	05 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/07/04	05 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/06/09	05 : 31	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd
2023/06/05	20 : 00	GlobeNewswire Inc.	BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis	NASDAQ:BVXV	BiondVax Pharmaceuticals Ltd